News
- General News
- World News
- Education
- Climate Change
- Covid-19
- Featured News
- Organisations
- Politics
- Photo Gallery
- Healthcare
- Politics & International Affairs
- Lifestyle
- Health
- Stock Market
- Commodities
- Latest
- Sports
- Economy
- Forex/Currency
- Cryptocurrency
- Live News
- IPO
- Market Updates
- Accidents
- Aerospace & Defense
- Agriculture
- Auto
- Technology
- Basic Materials
- Crime
- Energy
- Environment
- Pharma
- Real Estate
- Religion
- Sports News
- Entertainment News
Business News
Trending Stocks
Companies
Companies

Your go-to page for detailed info on US-listed companies – from their origin to latest updates to contact information.
- Consumer
- Energy
- Financial
- Healthcare
- Industrial
- Media
- Mining
- Oil and Gas
- Real Estate
- Retail
- Technology
- Telecommunication
Videos
Education
Education

Seasoned investors or newbie traders, our financial education corner has something for everyone.
Buzzing Trends
Buzzing Trends

Most talked-about topics globally, and why they matter.
Entertainment
Our Products
Sports
- Cricket
- Football
- Tennis
- Golf
- Basketball
- Formula One
- Boxing
- Other Sports
Science

89Bio's NASH drug meets main goals of mid-stage study

March 22, 2023 04:42 AM PDT | By Reuters

Follow us on Google News:

89Bio's NASH drug meets main goals of mid-stage study — Image source: ©2022 Kalkine Media®

Recent News

Trading at Bargain: Examining the Opportunities with NYSE Penny Stocks

Profitable Payouts: Delving into the Accomplishments of Four NYSE Divi...

Route 66 TV star George Maharis dies aged 94

Jurors to resume deliberations next week in rape trial of actor Master...

(Adds updated share movement, and trial details)

March 22 (Reuters) - Drug developer 89Bio Inc said on Wednesday its treatment for a liver disease called non-alcoholic steatohepatitis met the main goals of a mid-stage trial, sending its shares up 50% in premarket trading.

The company's experimental drug, Pegozafermin, demonstrated at least one-stage fibrosis improvement without worsening of NASH and NASH resolution without worsening of fibrosis in both trial doses.

89Bio said the data supports advancement to late-stage development.

(Reporting by Pratik Jain in Bengaluru; Editing by Sriraj Kalluvila)

Disclaimer

The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.